Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

Abstract

Background Approximately 10-15% of triple negative breast cancers (TNBCs) have deleterious mutations in BRCA1 and BRCA2 and may benefit from polyadenosine 5’diphosphoribose polymerase (PARP) inhibitor treatment. PARP inhibitors may also increase exogenous replication stress and thereby increase sensitivity to inhibitors of ataxia telangiectasia and Rad3-related protein (ATR). This phase II study examined the activity of the combination of PARP inhibitor, Olaparib, and ATR inhibitor, celerasertib (AZD6738), in patients with advanced TNBC. Patients and methods Patients with TNBC on most recent biopsy who had received 1 or 2 lines of chemotherapy for advanced disease or had relapsed within 12 months of (neo)adjuvant chemotherapy were eligible. Treatment was olaparib 300mg twice a day continuously and celarasertib 160mg on days 1–7 on a 28 day cycle until disease progression. The primary endpoint was confirmed objective response rate (ORR). Tissue and plasma biomarker analyses were pre-planned to identify predictors of response. Results 70 evaluable patients were enrolled. Germline BRCA1/2 mutations were present in 10 (14%) patients and 3 (4%) patients had somatic BRCA mutations. The confirmed ORR was 12/70; 17.1% (95%CI: 10.4-25.5). Responses were observed in patients without germline or somatic BRCA1/2 mutations, including patients with mutations in other homologous recombination repair genes and tumours with functional homologous recombination deficiency by RAD51 foci. Conclusion The response rate to olaparib and ceralasertib did not meet pre-specified criteria for activity in the overall evaluable population, but responses were observed in patients who would not be expected to respond to Olaparib monotherapy.

People
Ring, Alistair
Author

Kingston, Belinda and Pearson, Alex and Herrera-Abreu, Maria Teresa and Sim, Li-Xuan and Cutts, Rosalind J. and Shah, Heena and Moretti, Laura and Kilburn, Lucy S. and Johnson, Hannah and Macpherson, Iain R. and Ring, Alistair and Bliss, Judith M. and Hou, Yingwei and Toy, Weiyi and Katzenellenbogen, John A. and Chandarlapaty, Sarat and Turner, Nicholas C. (2024) ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer Discovery, 14 (2). pp. 274-289. ISSN 2159-8274

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Kilburn, Lucy S.
Author

Kingston, Belinda and Pearson, Alex and Herrera-Abreu, Maria Teresa and Sim, Li-Xuan and Cutts, Rosalind J. and Shah, Heena and Moretti, Laura and Kilburn, Lucy S. and Johnson, Hannah and Macpherson, Iain R. and Ring, Alistair and Bliss, Judith M. and Hou, Yingwei and Toy, Weiyi and Katzenellenbogen, John A. and Chandarlapaty, Sarat and Turner, Nicholas C. (2024) ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer Discovery, 14 (2). pp. 274-289. ISSN 2159-8274

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Pearson, Alex
Author

Kingston, Belinda and Pearson, Alex and Herrera-Abreu, Maria Teresa and Sim, Li-Xuan and Cutts, Rosalind J. and Shah, Heena and Moretti, Laura and Kilburn, Lucy S. and Johnson, Hannah and Macpherson, Iain R. and Ring, Alistair and Bliss, Judith M. and Hou, Yingwei and Toy, Weiyi and Katzenellenbogen, John A. and Chandarlapaty, Sarat and Turner, Nicholas C. (2024) ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer Discovery, 14 (2). pp. 274-289. ISSN 2159-8274

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Moretti, Laura
Author

Kingston, Belinda and Pearson, Alex and Herrera-Abreu, Maria Teresa and Sim, Li-Xuan and Cutts, Rosalind J. and Shah, Heena and Moretti, Laura and Kilburn, Lucy S. and Johnson, Hannah and Macpherson, Iain R. and Ring, Alistair and Bliss, Judith M. and Hou, Yingwei and Toy, Weiyi and Katzenellenbogen, John A. and Chandarlapaty, Sarat and Turner, Nicholas C. (2024) ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer Discovery, 14 (2). pp. 274-289. ISSN 2159-8274

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Afshari-Mehr, Angelica
Author

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Wardley, Andrew M.
Author

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Gurel, Bora
Author

Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Macpherson, Iain R.
Author

Maldonado, Horacio and Dreger, Marcel and Bedgood, Lara D. and Kyriakou, Theano and Wolanska, Katarzyna I. and Rigby, Megan E. and Marotta, Valeria E. and Webster, Justine M. and Wang, Jun and Rusilowicz-Jones, Emma V. and Marshall, John F. and Coulson, Judy M. and MacPherson, Iain R. and Hurlstone, Adam and Morgan, Mark R. (2024) A trafficking regulatory subnetwork governs α V β 6 integrin-HER2 cross-talk to control breast cancer invasion and drug resistance. Science Advances, 10 (49): eadk9944. ISSN 2375-2548

Hanna, Daire and Merrick, Sophie and Ghose, Aruni and Devlin, Michael John and Yang, Dorothy D. and Phillips, Edward and Okines, Alicia and Chopra, Neha and Papadimatraki, Elisavet and ROSS, KIRSTY and MacPherson, Iain and Boh, Zhuang Y. and Michie, Caroline O. and Swampillai, Angela and Gupta, Sunnia and Robinson, Tim and Germain, Lewis and Twelves, Chris and Atkinson, Charlotte and Konstantis, Apostolos and Riddle, Pippa and Cresti, Nicola and Naik, Jay D. and Borley, Annabel and Guppy, Amy and Schmid, Peter and Phillips, Melissa (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. British Journal of Cancer, 130 (12). pp. 1916-1920. ISSN 0007-0920

Agnew, Sommer and Crawford, Megan and MacPherson, Iain and Shiramizu, Victor and Fleming, Leanne (2024) The impact of symptom clusters on endocrine therapy adherence in patients with breast cancer. Breast, 75: 103731. ISSN 0960-9776

See full publications list
Riisnaes, Ruth
Author

Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Baird, Richard D.
Author

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Martin, Sue
Author

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Roylance, Rebecca
Author

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Johnson, Hannah
Author

Kingston, Belinda and Pearson, Alex and Herrera-Abreu, Maria Teresa and Sim, Li-Xuan and Cutts, Rosalind J. and Shah, Heena and Moretti, Laura and Kilburn, Lucy S. and Johnson, Hannah and Macpherson, Iain R. and Ring, Alistair and Bliss, Judith M. and Hou, Yingwei and Toy, Weiyi and Katzenellenbogen, John A. and Chandarlapaty, Sarat and Turner, Nicholas C. (2024) ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer Discovery, 14 (2). pp. 274-289. ISSN 2159-8274

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Ferreira, Ana
Author

Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Winter, Matthew C.
Author

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Dunne, Kathryn
Author

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Copson, Ellen
Author

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Hickish, Tamas
Author

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Burcombe, Russell
Author

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Randle, Kat
Author

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Serra, Violeta
Author

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Llop-Guevara, Alba
Author

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Bliss, Judith M.
Author

Kingston, Belinda and Pearson, Alex and Herrera-Abreu, Maria Teresa and Sim, Li-Xuan and Cutts, Rosalind J. and Shah, Heena and Moretti, Laura and Kilburn, Lucy S. and Johnson, Hannah and Macpherson, Iain R. and Ring, Alistair and Bliss, Judith M. and Hou, Yingwei and Toy, Weiyi and Katzenellenbogen, John A. and Chandarlapaty, Sarat and Turner, Nicholas C. (2024) ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer Discovery, 14 (2). pp. 274-289. ISSN 2159-8274

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Turner, Nicholas C.
Author

Kingston, Belinda and Pearson, Alex and Herrera-Abreu, Maria Teresa and Sim, Li-Xuan and Cutts, Rosalind J. and Shah, Heena and Moretti, Laura and Kilburn, Lucy S. and Johnson, Hannah and Macpherson, Iain R. and Ring, Alistair and Bliss, Judith M. and Hou, Yingwei and Toy, Weiyi and Katzenellenbogen, John A. and Chandarlapaty, Sarat and Turner, Nicholas C. (2024) ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer Discovery, 14 (2). pp. 274-289. ISSN 2159-8274

Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

See full publications list
Texts
433:449
lightbox image
307734.pdf - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview
Information
Title:
Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010)
Creators:
Ring, Alistair and Kilburn, Lucy S. and Pearson, Alex and Moretti, Laura and Afshari-Mehr, Angelica and Wardley, Andrew M. and Gurel, Bora and MacPherson, Iain R. and Riisnaes, Ruth and Baird, Richard D. and Martin, Sue and Roylance, Rebecca and Johnson, Hannah and Ferreira, Ana and Winter, Matthew C. and Dunne, Kathryn and Copson, Ellen and Hickish, Tamas and Burcombe, Russell and Randle, Kat and Serra, Violeta and Llop-Guevara, Alba and Bliss, Judith M. and Turner, Nicholas C.
Identification Number:
10.1158/1078-0432.CCR-23-1696
Date:
1 December 2023
Divisions:
College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Publisher:
American Association for Cancer Research
Additional Information:
This research was funded by the Stand Up to Cancer Campaign for Cancer Research UK (CRUK/15/010, C30746/A19505, S. Martin, H. Johnson, L. Moretti) with additional support from AstraZeneca, Guardant Health, BioRad and Asociación Española Contra el Cáncer (AECC, INVES20095LLOP A. Llop‐Guevara). The ICR Clinical Trials and Statistics Unit is supported by the Cancer Research UK core programme grant (C1491/A25351 L Kilburn).
Library
URI:
https://pub.demo35.eprints-hosting.org/id/eprint/433
Item Type:
Article
Depositing User:
Unnamed user with email ejo1f20@soton.ac.uk
Date Deposited:
11 Jun 2025 16:38
Revision:
13
Last Modified:
12 Jun 2025 08:59
View Item